Refractory Status Epilepticus

 

Refractory Status Epilepticus in the ICU: Current Approaches to Management

Dr Neeraj Manikath ,Claude.ai

Abstract

Refractory status epilepticus (RSE) represents a neurological emergency with significant morbidity and mortality. This review examines the definition, etiology, pathophysiology, and current evidence-based management approaches for RSE in the intensive care unit (ICU). We discuss the pharmacological interventions, including anesthetic agents, newer antiseizure medications, and immunomodulatory therapies, as well as non-pharmacological modalities such as neuromodulation. Additionally, we explore monitoring strategies, prognostic factors, and emerging therapies to guide clinical decision-making for this challenging condition.

Introduction

Status epilepticus (SE) is defined as a seizure lasting more than 5 minutes or multiple seizures without recovery of consciousness between them. Refractory status epilepticus (RSE) occurs when seizures persist despite adequate doses of initial benzodiazepines and at least one appropriate antiseizure medication (ASM). Super-refractory status epilepticus (SRSE) is defined as status epilepticus that continues or recurs 24 hours or more after the initiation of anesthetic therapy, including cases where seizures recur upon reduction or withdrawal of anesthesia.

RSE represents approximately 30-40% of all SE cases and is associated with mortality rates ranging from 30% to 50%, while SRSE carries an even higher mortality risk. This review focuses on the optimal management approaches for RSE in the intensive care unit setting, with emphasis on recent advances and evidence-based strategies.

Epidemiology and Etiology

The incidence of SE is estimated at 10-41 cases per 100,000 population annually, with approximately one-third progressing to RSE. The etiology of RSE is diverse and can be categorized as:

1. Acute symptomatic causes: Stroke, traumatic brain injury, CNS infections (encephalitis, meningitis), hypoxic-ischemic encephalopathy, metabolic disturbances, and drug toxicity or withdrawal.

2. Remote symptomatic causes: Previous stroke, CNS malformations, tumor, or trauma.

3. Progressive symptomatic causes: Brain tumors, neurodegenerative disorders, and autoimmune encephalitis.

4. Cryptogenic: No identifiable cause despite extensive investigation.

Autoimmune etiologies are increasingly recognized as important causes of RSE, including anti-NMDA receptor encephalitis, anti-LGI1 encephalitis, GAD65 antibody-associated encephalitis, and other autoantibody-mediated disorders.

Pathophysiology

The transition from isolated seizures to RSE involves multiple mechanisms:

1. Receptor trafficking: Prolonged seizures lead to internalization of inhibitory GABA-A receptors and externalization of excitatory NMDA receptors, creating a pro-excitatory state.

2. Neuroinflammation: Seizures trigger inflammatory cascades with microglial activation and cytokine release, which contribute to hyperexcitability and blood-brain barrier disruption.

3. Mitochondrial dysfunction: Prolonged seizures cause energy failure, contributing to excitotoxicity and neuronal death.

4. Pharmacoresistance: Dynamic changes in drug transporters and targets contribute to decreased effectiveness of ASMs over time.

Understanding these mechanisms is essential for developing rational treatment approaches for RSE.

Diagnosis and Evaluation

Clinical Assessment

Prompt recognition of RSE is crucial. Clinical manifestations may range from obvious convulsive activity to subtle signs such as eye deviation, nystagmus, or twitching of the face or extremities. In many cases, particularly after initial treatment, RSE may present as nonconvulsive status epilepticus (NCSE), which requires EEG for detection.

Diagnostic Workup

1. Continuous EEG monitoring: Essential for diagnosis and management, allowing detection of NCSE and assessment of treatment response.

2. Neuroimaging: Brain MRI should be performed to identify structural abnormalities, signs of inflammation, or other etiologies.

3. Laboratory investigations:

   • Complete blood count, comprehensive metabolic panel, toxicology screen
   • CSF analysis when infection or autoimmune etiology is suspected
   • Autoimmune panels including anti-NMDAR, anti-LGI1, anti-CASPR2, anti-GAD65, and other relevant autoantibodies
   • Metabolic and genetic testing in selected cases

Management Approaches

Management of RSE involves a staged approach, with escalating interventions as the condition proves resistant to treatment.

Stage 1: Initial Stabilization

• Airway management, hemodynamic support, and treatment of precipitating causes
• Administration of benzodiazepines (lorazepam, diazepam, or midazolam)
• Initiation of loading doses of ASMs (e.g., phenytoin/fosphenytoin, valproate, levetiracetam)

Stage 2: Management of Established RSE

When seizures continue despite appropriate doses of benzodiazepines and at least one ASM, treatment escalates to anesthetic agents:

Anesthetic Agents

1. Propofol:

   • Dosing: 1-2 mg/kg loading dose, followed by 30-200 μg/kg/min infusion
   • Advantages: Rapid onset and offset, minimal accumulation
   • Disadvantages: Propofol infusion syndrome (with prolonged high-dose use), hypotension, hypertriglyceridemia
   • EEG target: Burst suppression with interburst interval of 2-10 seconds

2. Midazolam:

   • Dosing: 0.2 mg/kg loading dose, followed by 0.05-2 mg/kg/hr infusion
   • Advantages: Less hypotension than propofol, may have neuroprotective effects
   • Disadvantages: Tachyphylaxis, accumulation with prolonged use
   • EEG target: Burst suppression or seizure suppression

3. Ketamine:

   • Dosing: 1-3 mg/kg loading dose, followed by 1-10 mg/kg/hr infusion
   • Advantages: Acts at NMDA receptors (distinct mechanism), relatively stable hemodynamics
   • Disadvantages: Sympathomimetic effects, potential neurotoxicity at high doses
   • Often used as adjunctive therapy with propofol or midazolam

4. Pentobarbital/Thiopental:

   • Dosing: Pentobarbital 5-15 mg/kg loading dose, followed by 0.5-5 mg/kg/hr
   • Advantages: Potent anti-seizure effects
   • Disadvantages: Significant hypotension, prolonged recovery, immunosuppression
   • Generally reserved for cases refractory to other anesthetics

Stage 3: Super-Refractory Status Epilepticus

When seizures persist despite 24 hours of anesthetic therapy or recur upon weaning of anesthetics, additional strategies include:

Pharmacological Approaches

1. Alternative Antiseizure Medications:

   • Perampanel (AMPA receptor antagonist): 8-12 mg daily
   • Brivaracetam: 50-200 mg daily
   • Stiripentol: 50 mg/kg/day (maximum 4000 mg/day)
   • Lacosamide: 200-400 mg daily
   • Topiramate: Up to 1000 mg daily (in divided doses)

2. Immunomodulatory Therapies:

   • High-dose corticosteroids (methylprednisolone 1000 mg IV daily for 3-5 days)
   • Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days
   • Plasma exchange (5-7 exchanges over 10 days)
   • Rituximab (375 mg/m² weekly for 4 weeks)
   • Cyclophosphamide (750 mg/m² monthly)

3. Other Pharmacological Options:

   • Magnesium sulfate: 4-6 g loading dose followed by infusion to maintain serum levels 3.5-7 mEq/L
   • Pyridoxine: Particularly in young patients with unexplained RSE
   • Allopurinol: As an adjunctive therapy in selected cases
   • Ketogenic diet: Administered via enteral feeding

Non-Pharmacological Interventions

1. Neuromodulation Techniques:

   • Vagus nerve stimulation (VNS)
   • Deep brain stimulation (DBS)
   • Responsive neurostimulation (RNS)
   • Transcranial magnetic stimulation (TMS)
   • Electroconvulsive therapy (ECT)

2. Surgical Interventions:

   • Focal resection when a clear epileptogenic zone is identified
   • Multiple subpial transections
   • Corpus callosotomy
   • Hemispherectomy in selected cases

Monitoring and Supportive Care

Neuromonitoring

1. Continuous EEG monitoring: Essential for assessing treatment response and titrating anesthetic agents.

2. EEG targets: Typically burst suppression with interburst interval of 2-10 seconds, though seizure suppression without burst suppression may be adequate in some cases.

3. Duration of treatment: Generally maintained for 24-48 hours before attempting gradual withdrawal of anesthetics.

ICU Management Considerations

1. Airway and ventilation: Lung-protective ventilation strategies should be employed.

2. Hemodynamics: Vasopressors may be required to maintain cerebral perfusion pressure.

3. Neuroprotection: Temperature management (target normothermia or mild hypothermia 35-36°C).

4. Prevention of complications: DVT prophylaxis, stress ulcer prophylaxis, infection prevention.

5. Nutrition: Early enteral nutrition when possible.

Emerging Therapies and Future Directions

1. Novel ASMs: Cenobamate, ganaxolone, and other drugs in development.

2. Neurosteroids: Allopregnanolone derivatives.

3. Anti-inflammatory approaches: Targeted cytokine antagonists, microglial inhibitors.

4. Precision medicine: Pharmacogenomics and biomarker-guided therapy.

5. Closed-loop systems: EEG-guided automated medication delivery.

Prognosis and Outcomes

Prognostic factors in RSE include:

1. Etiology: Acute symptomatic causes generally have worse outcomes than other etiologies.

2. Age: Advanced age is associated with higher mortality.

3. Duration: Longer duration of RSE correlates with poorer outcomes.

4. Comorbidities: Pre-existing medical conditions affect survival.

5. EEG patterns: Certain patterns (e.g., generalized periodic discharges with triphasic morphology) may indicate worse prognosis.

Outcomes assessment should include not only mortality but functional status, cognitive outcomes, and quality of life.

Conclusion

RSE represents a significant challenge in neurocritical care. A systematic approach to diagnosis and management, with early recognition and prompt, aggressive treatment, is essential. The optimal management requires a multidisciplinary team including neurointensivists, epileptologists, and critical care specialists. Future research should focus on identifying biomarkers to guide precision therapy, developing novel therapeutic agents targeting the underlying pathophysiology, and establishing evidence-based protocols to improve outcomes.

References

1. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus - Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523.

2. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(10):2802-2818.

3. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10(10):922-930.

4. Holtkamp M, Meierkord H. Nonconvulsive status epilepticus: a diagnostic and therapeutic challenge in the intensive care setting. Ther Adv Neurol Disord. 2011;4(3):169-181.

5. Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498-1503.

6. Zeiler FA, Zeiler KJ, Teitelbaum J, et al. Modern intravenous anesthetics for refractory status epilepticus: a systematic review. Can J Neurol Sci. 2015;42(2):106-115.

7. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82(8):656-664.

8. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(8):2314-2328.

9. Kirmani BF, Shetty AK, Shetty N, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurol Clin Pract. 2020;10(4):320-327.

10. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393-404.

11. Görgülü A, Unal M, Bakır A, et al. Effect of perampanel on status epilepticus and super-refractory status epilepticus: a systematic review. Seizure. 2021;86:158-165.

12. Cervenka MC, Hocker S, Koenig M, et al. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. Neurology. 2017;88(10):938-943.

13. Fang Y, Wang X. Ketamine for the treatment of refractory status epilepticus. Seizure. 2015;30:14-20.

14. Kokate TG, Banks MK, Magee T, et al. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther. 1999;288(2):679-684.

15. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.

16. Trinka E, Höfler J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012;53(Suppl 4):127-138.

17. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61.

18. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.

19. Claassen J, Taccone FS, Horn P, et al. Recommendations on the use of EEG monitoring in critically ill patients: consensus statement from the neurointensive care section of the ESICM. Intensive Care Med. 2013;39(8):1337-1351.

20. Leitinger M, Trinka E, Gardella E, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a systematic review. Lancet Neurol. 2016;15(10):1054-1062.